​

Funding Round

Series C - Tarveda Therapeutics

Series C - Tarveda Therapeutics

Investment Firm

Overview

Tarveda Therapeutics is a developer of miniature drug conjugates designed for the treatment of patients with a wide range of solid tumors.

Announced Date

Jan 27, 2016

Funding Type

Series C

Highlights

Location

United States, North America

Social

Investor Lead

Novo Holdings

Novo Holdings

Novo Holdings is a debt and early_stage_venture and late_stage_venture and post_ipo and private_equity and secondary_market and seed and venture firm.

Participant Investors

2

Investor Name
Participant InvestorNovo Holdings
Participant InvestorNew Enterprise Associates

Round Details and Background

Tarveda Therapeutics raised $38000000 on 2016-01-27 in Series C

Tarveda Therapeutics is a developer of miniature drug conjugates designed for the treatment of patients with a wide range of solid tumors.

Company Funding History

9

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Jan 07, 2015
Series B - Tarveda Therapeutics
4-21.0M
Mar 12, 2014
Venture Round - Tarveda Therapeutics
-1.0M
Dec 24, 2013
Series B - Tarveda Therapeutics
3-21.0M
Jan 06, 2012
Series A - Tarveda Therapeutics
3-2.8M

Recent Activity

There is no recent news or activity for this profile.